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Abstract
Background: Taxanes are known to cause onychopathy. Previous studies have reported the relationship between
onychopathy and paclitaxel dosing intervals and cumulative doses. However, there are no studies of the predictive
factors for docetaxel-induced nail changes. The present study used the drug accumulation rate (mg/m2/day) as a
novel indicator and evaluated its usefulness for the prediction of onychopathy.
Methods: From January 2008 to December 2009, we examined patients who received docetaxel at the Toyama
University Hospital and Tonami General Hospital to determine the time to onset of onychopathy, the accumulation
rate, and the cumulative dose. We then divided the study subjects into two groups, and used Receiver Operating
Characteristic (ROC) analysis to calculate a cut-off value. We evaluated both indicators as predictive factors for
onychopathy using the log-rank test and Cox proportional hazards model.
Results: Ninety-five patients were included in the present study. The results of the log-rank test sub-analysis
revealed that the median number of days until onychopathy onset was significantly shorter in patients with an
accumulation rate greater than the cut-off (P = 0.009), and in those with a cumulative dose below the cut-off
(P < 0.001). The hazard ratios for the accumulation rate and cumulative dose, evaluated using Cox proportional
hazards regression analysis, were 1.44 (P = 0.036) and 0.99 (P < 0.001), respectively.
Conclusions: The results of the present study indicated that the drug accumulation rate influenced the time
to onset of docetaxel-induced onychopathy.
Trial registration: This study is not applicable for trial registration due to retrospective chart review without
intervention.
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Background
Skin disorders caused by anticancer drugs are known
to significantly affect quality of life when they become
serious [1]. However, there may be differences in the
evaluation of the severity of these symptoms by pa-
tients and medical practitioners. In addition, the
concordance rate between these two types of evalu-
ation also changes, depending on when they are per-
formed. In particular, under-reporting of onychopathy
by medical practitioners during clinical trials of anti-
cancer drugs has been identified as a problem [2].
Therefore, it is important to determine the time of
onychopathy onset, in order to perform accurate evalu-
ations in a timely manner [3].
Onychopathy is a skin disorder that is known to impact
on patient quality of life. The results of a clinical trial
comparing weekly and tri-weekly administration of pacli-
taxel (PTX) indicated that onychopathy may arise due to
the administration interval and the cumulative dosage,
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rather than occurring in response to a single dose [4].
Therefore, the exposure frequency and duration of use
were thought to determine the risk for onset of onychopa-
thy in patients receiving docetaxel (DTX), which is an-
other taxane anticancer drug [5].
On the other hand, doxorubicin (like DTX) is a
concentration-dependent drug and its accumulation rate
has been identified as a new predictive indicator for the
time of cardiotoxicity onset [6]. The accumulation rate
may therefore provide a predictive factor for the onset of
onychopathy in patients receiving DTX. If this point can
be clarified, it could improve the accuracy of predictions
of the time of onychopathy onset, thus facilitating the
establishment of more suitable intervention plans.
The present study focused on cumulative DTX dosage
and accumulation rate in order to evaluate their utility
as predictive factors for the time of onychopathy onset.
Methods
Study design
This multicenter retrospective cohort study was per-
formed after having obtained the approval of the
Toyama University Hospital Institutional Review Board
(approval no. 126) and the Tonami General Hospital
Institutional Review Board (approval no. 26003).
Subjects
The subjects were patients administered DTX in the
2 years from January 2008 to December 2009 at the out-
patient chemotherapy center of Toyama University
Hospital and at the outpatient chemotherapy depart-
ment of Tonami General Hospital. The observation
period was from the date of DTX administration until
the date that DTX treatment was discontinued. The per-
formance status of the study subjects was 0 or 1. Fur-
thermore, patients with onychopathy of Grade 1 or
higher at the start of DTX administration were excluded
from the study, as were patients with a history of DTX
administration within the past 3 months.
Investigation methods
Outcome: The primary outcome was the onset of ≥
Grade 1 onychopathy, diagnosed in accordance with the
Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0.
Determination of onychopathy: The nails of both the
hands were observed by the pharmacist in charge or by
the nurse at the patients’ outpatient visits. The grade of
onychopathy was determined using the CTCAE and en-
tered into each patient’s electronic chart.
Investigation items: For each subject, we recorded the
current regimen name, sex, age, performance status,
body surface area, underlying diseases, start-date for
DTX administration, end-date of DTX administration,
date of onychopathy onset, grade, name of previous regi-
men, interval between previous and current regimens,
number of days until onset of onychopathy, treatment
period with DTX (days), mean administration interval,
full cumulative dose of DTX (mg), use of several 5-FU
derivatives (5-fluorouracil, capecitabine, tegafur/gimera-
cil/oteracil), and blood hemoglobin level (g/dL).
The DTX treatment period was defined as the time
from DTX administration initiation to the first obser-
vation of onychopathy (for those who developed ony-
chopathy) or to the pre-defined end-date of DTX
treatment.
The mean administration interval was derived by div-
iding the number of DTX treatment days by the number
of DTX administrations. The cumulative dose (mg/m2)
was derived by dividing the sum of the DTX doses ad-
ministered during the treatment period by the patient’s
body surface area. The accumulation rate (mg/m2/day)
was derived by dividing the cumulative dosage of DTX
by the number of days of treatment with DTX.
Statistical analysis
For the univariate analysis, cut-off values were calculated
using the mean of each of the candidate predictive fac-
tors (cumulative dosage or accumulation rate), and these
were used to divide the subjects into two groups: a High
Group (Group H), at or above the cut-off value, and a
Low Group (Group L), below the cut-off. Kaplan-Meier
curves were plotted and Log-rank testing was performed
in order to study the correlation between the cumulative
dose of DTX and the accumulation rate with the num-
ber of days until the onset of onychopathy.
In addition, a multivariate analysis was conducted. The
number of days until the onset of onychopathy was
treated as the response variable, both the cumulative
dose (mg/m2) and the accumulation rate (mg/m2/day)
were treated as predictive factors, and Cox’s propor-
tional hazard analysis was performed. Other variables
that affect the onset of onychopathy, as well as nail
growth (age, body surface area, presence of several 5-FU
derivatives administration, and hemoglobin level) were
selected as covariates and analyzed as descriptive
variables, in tandem with the predictive factors.
Results
Subject characteristics
Ninety-five patients were administered DTX and also
satisfied the inclusion criteria at the start of DTX admin-
istration; 47 of these exhibited onychopathy during the
observation period (Fig. 1, Table 1). The mean cumula-
tive dose and accumulation rate values calculated by
ROC analysis were 112 mg/m2 and 2.1 mg/m2/day,
respectively. The patients were divided into Group H
and Group L on the basis of these cut-off values.
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In addition, 18 regimens had been used as previous
treatments and 33 patients had used concomitant several
5-FU derivatives. The mean time from the previous
treatment until the start of DTX administration was
112.5 ± 156.3 days (Table 2).
DTX, docetaxel; S-1, tegafur ∙ gimeracil ∙ oteracil;
PTX, paclitaxel; FEC, epirubicin + cyclophosphamide +
fluorouracil; FP, fluorouracil + cisplatin; XP, capecitabine
+ paclitaxel; AP, doxorubicin + paclitaxel; q3w, every
3 weeks; q6w, every 6 weeks; qw, every week; q2w, every
2 weeks.
Correlation between the onychopathy onset time and
each of the predictive factors (univariate analysis)
Figure 2 (a) and (b) show the Kaplan-Meier curves for
cumulative dose and accumulation rate respectively.
Log-rank testing found that the median number of days
until onychopathy onset was significantly shorter in pa-
tients classified as Group H by their accumulation rate
(P = 0.009), and in those classified as Group L by their
cumulative dose (P < 0.001) (Table 3).
Cox’s proportional hazard analysis (multivariate analysis)
This analysis identified the hazard ratio (HR) for cumula-
tive dose as a predictive factor, was 0.99 (p < 0.001), and
the only significant factor among the other covariates was
5-FU-derivative administration (HR = 0.23, p < 0.001). The
HR for accumulation rate as a predictive factor was 1.44
(p = 0.036), and the only significant factor among the
other covariates was age (HR = 0.97, p = 0.03) (Table 3).
CI, confidence interval; a)Log-rank test of the number of
days until onychopathy onset, expressed as the median
(range); b)Cox’s proportional hazard analysis with age,
body surface area, presence of several 5-FU derivatives
Fig. 1 Flowchart of the participating patients. DTX, docetaxel
Table 1 Patient characteristics
Characteristics Value (n = 95)
Age (mean years ± S.D.) 62.1 ± 12.0
Gender (n, male/female) 54/41
Body surface area (m2, mean ± S.D.) 1.57 ± 0.17
Concomitant use of 5-FU drugsa) (n, Y/N) 33/62
Hemoglobin at the start of administration
(mean g/dL ± S.D.)
11.2 ± 1.8
Primary site
Stomach, n (%) 32 (33.7)
Breast, n (%) 23 (24.2)
Lung, n (%) 19 (20.0)
Prostatic, n (%) 9 (9.5)
Others, n (%) 12 (12.6)
a)5-FU drugs: 5-fluorouracil, capecitabine, tegafur/gimeracil/oteracil
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administration, and hemoglobin (g/dL) as covariates;
c)Group H had accumulation rates of ≥ 2.5 mg/m2/day or
cumulative dosages of ≥ 200 mg/m2. Group L had levels
below these cut-off values.
Discussion
This study implied that the DTX accumulation rate is an
important determinant of the onset of DTX treatment-
associated onychopathy. The onset of onychopathy in-
duced by DTX reflects dose-dependent cumulative tox-
icity [7] and the accumulation rate also represents an
important factor predicting the severity of this adverse
event. Previous studies have shown wide variation in the
time of onset of onychopathy; this has therefore been
difficult to predict and tended to be overlooked, result-
ing in late diagnosis at a severe stage, and treatment by
dosage reduction or discontinuation [8]. Minisini [4] and
Takeshita et al. [9] reported that DTX-associated ony-
chopathy was present at earlier time-points than those
reported by clinical trials and emphasized that early
treatment was important. It is anticipated that the effect-
iveness of in-hospital risk management plans will be im-
proved by the use of more reliable predictive factors for
the time of onychopathy onset. This onset time informa-
tion will enable more attention to be directed to the
nails in the period during the appropriate time-period,
reducing the prevalence of treatment delays and of un-
treated onychopathy. In addition, this information will
improve understanding of the cause/effect relationship
between the causal drug and onychopathy, facilitating
rapid action.
In the present univariate analysis of the cumulative dose,
the number of days until onset of onychopathy was signifi-
cantly lower in Group L. This may have been because of
rather than the size of the cumulative dose affecting the
time to onset of onychopathy, the fact that administration
was discontinued after the appearance of onychopathy,
resulting in a lower cumulative dose. On the other hand,
univariate analysis of the accumulation rate identified sig-
nificantly fewer days until the onset of onychopathy in
Group H and multivariate analysis produced a hazard ra-
tio of 1.44. The most considerable reason for that could
be the reversibility of side effects. The longer drug holiday
periods will improve recovery of the damage that cells re-
ceived when the side effect is reversible.
Therefore it is necessary to consider ‘time’ as a factor
in order to predict the onset of side effects in this case.
On the other hand, the cumulative dose could directly
effect on cumulative damage in the case of doxorubicin-
induced cardiotoxicity and other side effects that are ir-
reversible, which predictive index is lifetime cumulative
dose no matter how long drug holiday periods are. The
accumulation rate (mg/m2/day) used in the present
study was very similar to the concept of dose intensity
(mg/m2/week). However, narrowly-defined, dose inten-
sity is often used as a theoretical measure of the inten-
sity of a regimen, whereas the accumulation rate (mg/
m2/day) allows for the inclusion of patient-specific dos-
age reductions and drug holiday periods. Therefore, the
accumulation rate can provide a more useful indicator
than dose intensity for drugs like DTX, which show a
long intracellular retention time and high concentration-
dependency [10].
The time to onset of onychopathy cannot be predicted
by the accumulated dose alone. We believe that the ac-
cumulation rate is appropriate for predicting when ony-
chopathy will appear. This is because the cut-off values
calculated from ROC analysis for the conventional accu-
mulated dose produced the paradoxical result that the
median value (time) to the onset of onychopathy was
longer in Group H, as shown in Fig. 2a.
This study had some noteworthy limitations. First, this
was a retrospective investigation and a prospective co-
hort study will be necessary in order to verify the
Table 2 Medication regimens of 47 patients who developed
onychopathy
Regimen Number Previous regimens
DTX (60-80)/q3w 20 Carboplatin + PTX (3)
Gefitinib (1)













S-1 (80)/DTX (40)/q3w 3 Cisplatin + irinotecan (1)
S-1 + cisplatin + DTX (1)
None (1)
DTX (30)/qw 1 None (1)





1 PTX + estramustine (1)
DTX (40)/q3w/carboplatin 4 Carboplatin + PTX (1)
None (3)
Irinotecan (60)/DTX (35)/q2w 1 AP (1)
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present results, including the causal relationship be-
tween the accumulation rate and onychopathy. Second,
because the onset of onychopathy was determined on
the date of the patient’s outpatient visit, there is a possi-
bility that the actual onset occurred earlier and this was
not necessarily accurate. And that is, the possibility that
the appearance of onychopathy after the discontinuation
of DTX administration was overlooked cannot thus be
ruled out. Third, because the number of cases was lim-
ited and the effects of previous treatments were not
taken into account in this study, verification will be ne-
cessary by studies that incorporate measures to
minimize the effects of previous treatments; this could
include studies of administration-naïve patients only, in
order to obtain more accurate results. However, despite
the above limitations, the implication that the
Fig. 2 Curves showing the rate of non-development of onychopathy by cumulative dose (a) and accumulation rate (b). When the cut-off value
for the accumulated dose was set at 112 mg/m2, the median value (time) before the onset of onychopathy was 156 days for Group H and 58 days
for Group L (p < 0.001). When the cut-off value for the accumulation rate was set at 2.1 mg/m2/day, the median value (time) was 105 days for
Group H and 172 days for Group L (p = 0.009)
Table 3 Correlation of onychopathy onset time with various predictive factors
Factor/Model Univariate analysisa) Multivariate analysisb)
Group H c) Group L c) P value Hazard ratio (95 % CI) P value
Accumulation rate (mg/m2/day) 104 (14-343) 159 (15-910) 0.024 1.4429 (1.0238, 2.0336) 0.0363
Cumulative dose (mg/m2) 204 (42-910) 77 (14-315) <0.001 0.9905 (0.9862, 0.9948) <0.001
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accumulation rate could provide a novel predictive fac-
tor for the onset of DTX-associated onychopathy has
important clinical ramifications. As described above, this
approach could improve understanding of the cause and
effect relationship between drug treatments and the on-
set of this condition, helping to reduce the level of un-
diagnosed onychopathy and minimize treatment delays.
Cancer chemotherapy is transitioning from an in-
patient procedure to an outpatient treatment. Depending
on the individual, there are cases where a patient does
not recognize that a skin disorder has occurred as an ad-
verse reaction to the anticancer drug. Even when the pa-
tient is aware of this, they often simply ignore it because
they consider it to present a minor inconvenience. This
study may also lead to further investigations of whether
the accumulation rate is also a better predictor of other
adverse reactions treated as cumulative toxicities, includ-
ing cisplatin-induced ototoxicity and oxaliplatin-induced
peripheral neuropathy [11].
Conclusion
The present study identified the DTX accumulation rate
as a possible new predictive factor for the onset of ony-
chopathy. In the future, it will be necessary to verify the
current results by conducting prospective observational
trials, and to explore whether the predictive accuracy
can be increased.
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